Jeffrey M. Leiden
2016 - Vertex Pharmaceuticals
In 2016, Jeffrey M. Leiden earned a total compensation of $17.4M as Chairman, President & CEO at Vertex Pharmaceuticals, a 38% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $2,246,400 |
---|---|
Option Awards | $4,060,397 |
Salary | $1,300,000 |
Stock Awards | $9,800,076 |
Other | $12,885 |
Total | $17,419,758 |
Leiden received $9.8M in stock awards, accounting for 56% of the total pay in 2016.
Leiden also received $2.2M in non-equity incentive plan, $4.1M in option awards, $1.3M in salary and $12.9K in other compensation.
Rankings
In 2016, Jeffrey M. Leiden's compensation ranked 170th out of 14,075 executives tracked by ExecPay. In other words, Leiden earned more than 98.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 170 out of 14,075 | 99th |
Division Manufacturing | 53 out of 5,489 | 99th |
Major group Chemicals And Allied Products | 15 out of 1,895 | 99th |
Industry group Drugs | 13 out of 1,538 | 99th |
Industry Pharmaceutical Preparations | 11 out of 1,176 | 99th |
Source: SEC filing on April 28, 2017.
Leiden's colleagues
We found five more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2016.
2016
Michael Parini
Vertex Pharmaceuticals
EVP & Chief Legal and Administrative Officer
2016
Ian Smith
Vertex Pharmaceuticals
Chief Financial Officer
2016
Stuart Arbuckle
Vertex Pharmaceuticals
EVP & Chief Commercial Officer
2016
Amit Sachdev
Vertex Pharmaceuticals
EVP & Chief Regulatory Officer
2016
David Altshuler
Vertex Pharmaceuticals